Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

18 May 2022

Albert Labs Granted Health Canada Licence

Albert Labs has been issued a Health Canada License enabling the possession, production, and delivery of psilocybin and other psychoactive controlled substances...

By Microdose NewsDesk

Finance

17 May 2022

MindMed Prepares to Raise Up to $100M in Capital

MindMed announced the approval for shares to be sold for up to $100,000,000 in aggregate sales in "at the market" transactions (at market price)...

By Microdose NewsDesk

Don’t Miss

16 May 2022

News You Might Have Missed: May 16th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

12 May 2022

Field Trip and Nue Life To Bring Psychedelic Therapy Home

Field Trip at Home™ Powered by Nue Life, was announced this morning, a partnership that provides ketamine treatments from the comfort of a person’s home....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Industry

11 May 2022

Breaking News: MindMed Announces Positive Results from Phase 2 LSD Trial

Microdose was at the event and the anticipation for MindMed's results was palpable....

By Microdose NewsDesk

Industry

10 May 2022

COMPASS Pathways to Fund Study of Psilocybin for Autism

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults...

By Microdose NewsDesk

Don’t Miss

9 May 2022

News You Might Have Missed: May 9th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic industry news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

6 May 2022

Wesana Plans to Sell Clinics, Focus on Drug Development

Looks like Wesana's positive meeting with the FDA regarding their lead compound has prompted a revised company game plan...

By Microdose NewsDesk

Industry

5 May 2022

MindBio Therapeutics Completes World’s First Microdosing Trial

MindBio Therapeutics Announces Completion of World First Phase 1 Microdosing Clinical Trial...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.